RBL2 and breast carcinoma: Circumstantial evidence supports the idea that aberrant promoter methylation might be the causative agent for reduced Rbl2/p130 expression and tumor initiation, and is worth exploring phenomenon as a new prognostic tool for breast cancer pathogenesis.